4.5 Interaction with other medicinal products and other forms of interaction   
 No dedicated  drug-drug interaction studies have been conducted.  Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co -admin istered medicinal products is expected.  
 As expected, concomitant use of the rescue medication C1 esterase inhibitor results in an additive effect on lanadelumab -c 
 HMWK response based on the mechanism of action (MOA) of lanadelumab and C1 esterase inhibitor (see section  5.1).  
 
